Phase 1 study and population PK/PD modeling of long-acting growth hormone, GB08, to guide pediatric dosing
GB08 provides notable advantages over traditional therapies, like short-acting GH, by enhancing treatment adherence and offering a potentially safer alternative. The findings from this study will guide dosing strategies for Phase 2 trial in children with GHD.
Authors
- Jiang Zhu (ORCID: https://orcid.org/0000-0001-9940-2496)
- Suofu Qin (ORCID: https://orcid.org/0000-0002-3323-8846)
- Wei Shang (ORCID: https://orcid.org/0000-0002-0086-0436)
- Jiajun Xu (ORCID: https://orcid.org/0000-0001-5010-2986)
- Wen He (ORCID: https://orcid.org/0000-0001-6119-971X)
- Hengxin Peng
- Yanqing Lin
Institutions
- WuXi AppTec (China) (CN)
- Chengdu Fifth People's Hospital (CN)
- Centre for Research and Development (ZW)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1093/ejendo/lvaf131
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 0.00